Table 2.
Descriptive statistics for %∆CDAI, ACR-N, and ∆HAQ-DI at month 12
| CDAI | ACR-N | HAQ-DI | ||||||
|---|---|---|---|---|---|---|---|---|
| Na |
Baseline, mean (SE) |
%∆ at month 12, mean (SE) |
Na |
At month 12, mean (SE) |
Na |
Baseline, mean (SE) |
∆ at month 12, mean (SE) |
|
| Tofacitinib monotherapy | 319 | 38.7 (0.7) | − 65.3 (1.8) | 320 | 32.2 (6.0) | 320 | 1.59 (0.04) | − 0.63 (0.04) |
| Tofacitinib + MTX | 309 | 40.5 (0.7) | − 74.0 (1.2) | 310 | 49.1 (2.1) | 311 | 1.57 (0.04) | − 0.67 (0.04) |
| ADA + MTX | 312 | 38.3 (0.8) | − 72.2 (1.4) | 314 | 45.1 (2.8) | 313 | 1.55 (0.04) | − 0.67 (0.03) |
∆, change from baseline; ACR-N, American College of Rheumatology response rate, where ACR is the percentage improvement from baseline in American College of Rheumatology components, and N represents the minimum percentage achieved by each patient; ADA, adalimumab; CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; SE, standard error
aNumber of patients with month 12 data for ≥ 1 efficacy endpoint